Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Mohamed A Kharfan-Dabaja^#¹, Razan Mohty^#², Neela Easwar³, Patrick Johnston⁴, Madiha Iqbal¹, Narendranath Epperla⁵, Jean Yared⁶, Nausheen Ahmed⁷, Mehdi Hamadani⁸, Amer Beitinjaneh⁹, Mayur Narkhede¹⁰, Deepa Jagadeesh¹¹, Praveen Ramakrishnan Geethakumari¹², Bhagirathbhai Dholaria¹³, Usama Gergis¹⁴, Javier Munoz¹⁵, Jose Sandoval-Sus¹⁶, Frederick L Locke², Joshua Fein³, Arushi Khurana⁴, Ernesto Ayala¹, Kaitlin Annunzio⁵, Aaron P Rapoport⁶, Forat Lutfi⁷, Othman Salim Akhtar⁸, Lazaros Lekakis⁹, Amitkumar Mehta¹⁰, Olalekan O Oluwole¹³, Jennifer Logue¹⁶, Michael D Jain², Tsiporah Shore³, Urshila Durani⁴, Muhamad Alhaj Moustafa¹, Joseph McGuirk⁷, Yi Lin⁴, Samuel Yamshon³, Julio C Chavez¹⁷

Affiliations

¹ Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
² Moffitt Cancer Center, Tampa, FL, USA.
³ Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
⁴ Mayo Clinic, Rochester, MN, USA.
⁵ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
⁶ Transplant and Cellular Therapy Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
⁷ Hematologic Malignancies and Cellular Therapeutics, Department of Medicine, University of Kansas Cancer Center, Westwood, KS, USA.
⁸ BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
¹⁰ Division of Hematology/Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA.
¹¹ Cleveland Clinic Foundation, Cleveland, OH, USA.
¹² Section of Hematologic Malignancies and Cellular Therapy, Division of Hematology and Oncology, at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
¹³ Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ Thomas Jefferson University, Philadelphia, PA, USA.
¹⁵ Mayo Clinic, Scottsdale, AZ, USA.
¹⁶ Moffitt Cancer Center at Memorial Health Care system, Pembroke Pines, FL, USA.
¹⁷ Moffitt Cancer Center, Tampa, FL, USA. julio.c.chavez@moffitt.org.

^# Contributed equally.

PMID: 40025178
DOI: 10.1038/s41409-025-02541-1

Observational Study

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Mohamed A Kharfan-Dabaja et al. Bone Marrow Transplant. 2025 May.

. 2025 May;60(5):632-639.

doi: 10.1038/s41409-025-02541-1. Epub 2025 Mar 1.

Authors

Affiliations

¹ Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA.
² Moffitt Cancer Center, Tampa, FL, USA.
³ Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
⁴ Mayo Clinic, Rochester, MN, USA.
⁵ The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
⁶ Transplant and Cellular Therapy Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
⁷ Hematologic Malignancies and Cellular Therapeutics, Department of Medicine, University of Kansas Cancer Center, Westwood, KS, USA.
⁸ BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
⁹ Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
¹⁰ Division of Hematology/Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA.
¹¹ Cleveland Clinic Foundation, Cleveland, OH, USA.
¹² Section of Hematologic Malignancies and Cellular Therapy, Division of Hematology and Oncology, at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
¹³ Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ Thomas Jefferson University, Philadelphia, PA, USA.
¹⁵ Mayo Clinic, Scottsdale, AZ, USA.
¹⁶ Moffitt Cancer Center at Memorial Health Care system, Pembroke Pines, FL, USA.
¹⁷ Moffitt Cancer Center, Tampa, FL, USA. julio.c.chavez@moffitt.org.

^# Contributed equally.

PMID: 40025178
DOI: 10.1038/s41409-025-02541-1

Abstract

Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety and efficacy of standard CD19 CAR T in patients 80 years of age or older. At total of 88 patients, median age 82 (range, 80-89) years, were included. Diffuse large B cell lymphoma (DLBCL) (N = 60, 68.2%) represented the most common histology. Patients were treated mostly with axicabtagene ciloleucel (N = 41, 46.6%) followed by lisocabtagene maraleucel (N = 25, 28.4%). Cytokine release syndrome (CRS) (any grade) was seen in 68 (77.3%) and 51 (58%) developed immune effector cell-associated neurotoxicity syndrome (ICANS). Incidence of grade 3-4 CRS and ICANS were 7.4% and 31.4%, respectively. For patients with DLBCL/tFL, the 1-year NRM, relapse, PFS, and OS were 11.6%, 40.8%, 47.6%, and 61.2%, respectively. We conclude that CAR T is feasible and effective in patients 80 years or older with B cell lymphomas. These patients must be provided the opportunity to be evaluated for this curative approach.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MAK-D reports grant/research from Bristol Myers Squibb, Novartis and Pharmacyclics, and lecture/honorarium from Kite Pharma; NE (Epperla) reports research funding from Beigene and Eli Lilly. Speakers Bureau for Beigene, Incyte, and Novartis. Ad board for ADC Therapeutics. NA reports Ad Board participation for Bristol Myers Squibb. Consultancy fees for Kite/ Gilead. MH reports research support/Funding: ADC Therapeutics, Spectrum Pharmaceuticals, Astellas Pharma. Consultancy: ADC Therapeutics, Omeros, CRISPR, BMS, Kite, AbbVie, Caribou, Genmab, Autolus. Speaker’s Bureau: ADC Therapeutics, AstraZeneca, Bei Gene, Kite. DMC: Inc, Genentech, Myeloid Therapeutics, CRISPR. PRG reports consultancy services to Kite/Gilead Pharma, Bristol Myers Squibb (BMS) and served on the advisory boards of Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals. AB reports honoraria from Autolus and Kite Pharma. BD reports stocks in Syndax and Iovance Biotherapeutics. Honoraria: MJH Healthcare Holdings, LLC, Curio Science, Gilead Sciences. Consulting/Advisory: Janssen Oncology, Boxer Capital, ADC Therapeutics, Ellipsis, Acrotech Biopharma. Speakers’ Bureau: Gilead Sciences. Research: Pfizer, Poseida therapeutics, MEI Pharma, Angiocrine Bioscience, Takeda, Janssen Oncology, WUGEN, Inc., Orca Bio, Gilead Sciences, AlloVir, Molecular Templates, Atara Biotherapeutics. Travel/accomodations: Poseida. UG reports research/grant support from Bristol Myers Sqibb, Kite Pharma and Novartis. Consultancy/speaker bureau from Kite Pharma. JM reports consulting for Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly. Research funding from Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene. Honoraria from Targeted Oncology, OncView, Curio, and Physicians’ Education Resource. JS-S reports Speaking for Pfizer (SeaGen) and Ad Board for SeaGen, MassiveBio, ADC therapeutics, Genmab, BeiGene, AbbVie, and Bristol Myers Squibb. FLL reports consulting/advisory role for Allogene, Amgen, bluebird bio, Bristol Myers Squibb, Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja Biopharma, and Wugen; research funding from Allogene, Kite, and Novartis; and patents, royalties, other intellectual property from several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. FL reports advisory board for ADC Therapeutics. OOO reports consultancy and advisory board for Pfizer, Kite, Gilead, AbbVie, Janssen, TGR therapeutics, ADC, Novartis, Epizyme, Curio science, Nektar, Cargo, Caribou. Institution funding from Kite, Pfizer, Daichi Sankyo, Allogene. Honoraria from Pfizer, Gilead. MDJ reports consultancy/advisory for Kite/Gilead, Novartis. Research funding from Kite/Gilead, Incyte, and Loxo@Lilly. TS reports consultancy for BioLine Rx. MAM reports consultancy for AbbVie. JMc reports consulting for Envision, Novartis, Caribou Bio, Sana Technologies, Legend Biotech. Ad Board participation for Autolus, Consulting/Ad Board for Kite/Scimentum, AlloVIr, Bristol Myers Squibb, CRISPR, Nektar. YL reports consulting/advisory board for Janssen, Sanofi, Bristol Myers Squibb, Regeneron, Genentech. Research from Janssen, Bristol Myers Squibb. Scientific Advisory Boards for NexImmune, Caribou. DSMB/EDMC for Pfizer. SY reports consulting for Bristol Myers Squibb and Advisory board for Kite Pharma. JCC Reports advisory/consulting role for Genmab, ADC Therapeutics, Kite/Gilead, Novartis, Astrazeneca, Cellectis, Allogene, BMS, Janssen, Abbvie, Beigene, Pfizer. Research support from Genmab, Merck, Janssen, RM, NE (Easwar), PJ, MI, MN, JF, EA, KA, APR, OSA, LL, JL declare no relevant conflicts of interest to disclose.

References

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. - DOI - PubMed - PMC
1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. - DOI - PubMed
1. Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. - DOI - PubMed
1. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91–103. - DOI - PubMed
1. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28:325–32. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Affiliations

Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources